中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.015 seconds)

    THE USE OF IMMATURE DENDRITIC CELLS TO SILENCE ANTIGEN SPECIFIC CD8+T CELL FUNCTION
    1.
    发明申请
    THE USE OF IMMATURE DENDRITIC CELLS TO SILENCE ANTIGEN SPECIFIC CD8+T CELL FUNCTION 审中-公开
    使用无髓树突状细胞消除抗原特异性CD8 + T细胞功能

    公开(公告)号：WO02056830A3

    公开(公告)日：2002-10-24

    申请号：PCT/US0150578

    申请日：2001-12-21

    Applicant: UNIV ROCKEFELLER ,  DHODAPKAR MADHAV V ,  STEINMAN RALPH M ,  BHARDWAJ NINA

    Inventor： DHODAPKAR MADHAV V ,  STEINMAN RALPH M ,  BHARDWAJ NINA

    IPC: A61K35/12 ,  A61K39/00 ,  C12N5/08 ,  A61K48/00 ,  C12N5/02 ,  C12N5/06

    CPC classification number: A61K39/0008 ,  A61K2035/122 ,  A61K2039/5154 ,  A61K2039/57

    Abstract: This invention provides methods for silencing a pre-existing immune response in a mammal, as for example, in the setting of autoimmune diseases. The method comprises administering to a mammal immature dendritic cells which have been contacted in vitro with an antigen, or to target the antigen to immature dendritic cells in vivo, in order to silence and/or suppress a pre-existing CD8+T cell immune response and induce IL-10 producing CD8+T cells in said mammal. This invention further relates to methods for propagating immature dendritic cells, for maintaining immaturity by modification ex vivo, and uses thereof, including generation of regulatory T cells for passive immunotherapy. The present invention also relates to compositions and kits comprising immature dendritic cells and antigens.

    Abstract translation: 本发明提供了使哺乳动物中预先存在的免疫应答沉默的方法，例如在自身免疫性疾病的设定中。 该方法包括给哺乳动物施用与抗原体外接触过的未成熟树突细胞，或将抗原靶向体内不成熟的树突细胞，以沉默和/或抑制预先存在的CD8 + T细胞免疫应答 并在所述哺乳动物中诱导产生IL-10的CD8 + T细胞。 本发明进一步涉及用于繁殖未成熟树突细胞，通过离体修饰保持未成熟的方法及其用途，包括产生用于被动免疫治疗的调节性T细胞。 本发明还涉及包含未成熟树突细胞和抗原的组合物和试剂盒。

    METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
    3.
    发明申请
    METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS 审中-公开
    树突细胞体外增殖的方法及其产生免疫原的用途

    公开(公告)号：WO1993020185A1

    公开(公告)日：1993-10-14

    申请号：PCT/US1993003141

    申请日：1993-04-01

    Applicant: STEINMAN, Ralph, M. ,  INABA, Kayo ,  SCHULER, Gerold

    IPC: C12N05/00

    CPC classification number: A61K39/0008 ,  A61K2035/122 ,  A61K2039/5154 ,  C12N5/0639 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/25

    Abstract: A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.

    Abstract translation: 提供了一种用于产生树突状细胞前体的增殖培养物的方法。 还提供了从增殖型树突状细胞前体在培养物中产生成熟树突状细胞的方法。 成熟树突细胞的培养提供了产生由树突状细胞修饰抗原或用抗原脉冲的树突状细胞的新型T细胞依赖性抗原的有效手段，包括微粒，该抗原在抗原活化的树突状细胞上被加工和表达。 本发明的新型抗原可以用作疫苗的免疫原或用于治疗疾病。 这些抗原也可用于治疗自身免疫性疾病，例如幼年型糖尿病和多发性硬化症。

    IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
    4.
    发明申请
    IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF 审中-公开
    鉴定DEC，（上皮和上皮细胞，205kDa），C型LECTIN域的受体，编码DEC的核酸及其用途

    公开(公告)号：WO1996023882A1

    公开(公告)日：1996-08-08

    申请号：PCT/US1996001383

    申请日：1996-01-31

    Applicant: THE ROCKEFELLER UNIVERSITY ,  STEINMAN, Ralph, M. ,  NUSSENZWEIG, Michel, C. ,  SWIGGARD, William, J. ,  JIANG, Wanping

    Inventor： THE ROCKEFELLER UNIVERSITY

    IPC: C12N15/12

    CPC classification number: C12N15/87 ,  A61K38/00 ,  A61K39/00 ,  A61K47/6425 ,  A61K2039/5154 ,  C07K14/4726 ,  C07K14/705

    Abstract: The present invention relates to the identification and characterization of a receptor associated with antigen presentation in immune responses, endocytosis, and transepithelial transport. Identification of the receptor, its characterization as having ten lectin-binding domains, and evidence of its role in the uptake and processing of oligosaccharides and oligosaccharide-decorated molecules, e.g. glycoproteins, has important ramifications for modifying immune response, and for trans-epithelial transport of molecules. The receptor, or integral membrane protein, termed herein "DEC", is found primarily on dendritic cells, but also found on B cells, brain capillaries, bone marrow stroma, epithelia of intestinal villi and pulmonary airways, as well as cortical epithelium of the thymus and the dendritic cells in the T cell areas of peripheral lymphoid organs. The murine and human counterparts of DEC have an apparent molecular mass of 205 kDa, the murine counterpart has an isoelectric point at pH 7.5, and carbohydrates comprise about 7 kDa of the total mass of murine DEC. The present invention is directed to identification of additional ligands of DEC, which can be advantageously targeted to dendritic cells and other cells that bear DEC. Targeting antigens for presentation by dendritic cells can provide for tolerance when the dendritic cells are quiescent, or for immune stimulation (i.e., vaccination) when the dendritic cells are activated, e.g., by stimulation with a cytokine or lymphokine, such as colony stimulating factor (CSF).

    Abstract translation: 本发明涉及与免疫反应，内吞作用和跨上皮转运中的抗原呈递相关的受体的鉴定和表征。 受体的鉴定，其表征具有十个凝集素结合结构域，以及其在寡糖和寡糖装饰分子的摄取和加工中的作用的证据，例如， 糖蛋白具有改变免疫应答和分子转跨上皮转运的重要影响。 本文称为“DEC”的受体或整合膜蛋白主要在树突状细胞上发现，但也发现于B细胞，脑毛细血管，骨髓基质，肠绒毛和肺气道上皮，以及皮质上皮细胞 胸腺和外周淋巴器官的T细胞区域中的树突状细胞。 DEC的鼠类和人类对应物具有205kDa的明显分子量，鼠对应物具有pH 7.5的等电点，碳水化合物包含鼠DEC总质量的约7kDa。 本发明涉及鉴定DEC的其它配体，其可以有利地靶向树突细胞和其他携带DEC的细胞。 当树突细胞被激活时，例如通过用细胞因子或淋巴因子的刺激，例如集落刺激因子（例如，通过刺激细胞因子或淋巴因子），树突细胞的靶向抗原可以提供树突状细胞静止时的耐受性，或用于免疫刺激（即疫苗接种） CSF）。

Patent Agency Ranking